E-Commerce Platforms Emerge as Primary Debut Channels for New Drugs in China

Major Chinese internet healthcare and e-commerce platforms have become primary launchpads for newly approved medicines, significantly accelerating drug availability across the country. According to Xinhua, out of roughly 120 new medicines commercially launched in China in 2025, leading online platforms debuted nearly or over 100 of them. Pharmaceutical executives and platform operators note that digital rollouts allow drugmakers to bypass multi-tiered offline distribution and lengthy hospital listing processes, enabling immediate, nationwide reach for patients in lower-tier cities and those requiring treatments for specialized indications.

Online debuts compress the multi-month—and often year-long—delays typically required for novel therapies to pass hospital pharmacy committee reviews and offline retail distribution. By connecting pharmaceutical manufacturers directly with patients through certified internet hospitals and smart fulfillment networks, digital channels are reshaping drug commercialization and improving equitable access for patients living outside tier-one metropolitan healthcare centers.

Major Chinese e-commerce and internet healthcare platforms have established themselves as primary commercial launch channels for innovative pharmaceuticals, altering the traditional route of hospital-centered drug distribution. According to a report by Xinhua, approximately 120 new medicines completed their initial commercial launch in China in 2025, with leading digital platforms hosting rollouts for nearly or more than 100 of these products. Under the conventional distribution pathway, new drugs face a prolonged journey even after completing provincial pricing registration. Securing hospital formulary access requires institutional pharmacy committee reviews, departmental approvals, and procurement filings—a process that frequently spans several months to a full year. In contrast, online commercial debuts enable pharmaceutical manufacturers to reach patients nationwide immediately upon regulatory approval. Several recent product launches illustrate this operational shift. In March, ruxolitinib phosphate cream, a vitiligo treatment, made its commercial debut on JD Health. Dr. Yang Qinping, a dermatology director at Huashan Hospital affiliated with Fudan University and an affiliated specialist with JD Internet Hospital, issued the initial online prescription. Prior to this online availability, patients in mainland China had to travel to the Boao Lecheng pilot zone in Hainan to access the therapy. Similarly, Novartis China's remibrutinib tablets for chronic spontaneous urticaria debuted digitally, allowing patients in smaller municipalities such as Ulanqab, Inner Mongolia, to receive prescribed treatments within one day. Platform operators and drugmakers attribute the rapid adoption of digital launches to channel efficiency and direct communication. Song Zhirui, vice president of JD Group and general manager of JD Health's pharmaceutical business department, stated that platforms function as connectors and accelerators in the industrial chain, closing the access gap between tier-one cities and remote areas. Zhang Ze, general manager of AliHealth's direct sales and drug platform divisions, highlighted that digital supply chains lower distribution and marketing overhead by eliminating multi-tiered intermediary networks. Domestic pharmaceutical manufacturers are also leveraging digital channels to address niche therapeutic segments. Liang Yumao, head of digital marketing for retail at Simcere Pharmaceutical, noted that digital platforms effectively combine product education with direct fulfillment, drastically reducing the operational burden of negotiating separately with fragmented offline hospital and pharmacy networks. Industry representatives from multinational firms like Novartis China added that digital platforms provide distinct coverage advantages for rare diseases and specialized indications.